Document Detail

Chronic heart failure patients with high collagen type I degradation marker levels benefit more with ACE-inhibitor therapy.
MedLine Citation:
PMID:  19958769     Owner:  NLM     Status:  MEDLINE    
Not all patients respond to angiotensin converting enzyme (ACE)-inhibitor equally. Genetic or other phenotypic variations might be useful in predicting the therapeutic efficacy of these drugs. With the present study we assessed the prognostic impact of ACE-inhibitor in chronic heart failure patients with different degrees of collagen metabolism as assessed by serum levels of a collagen type I degradation marker (CITP). One hundred ninety-six (126 male, 69+/-10 years) chronic heart failure patients were studied prospectively for 12 months regarding survival. Serum concentrations of CITP were measured at study entry. Chronic heart failure patients were divided into groups according to whether (n=114) or not (n=82) they received ACE-inhibitor as well as to their CITP levels. Survival (52.2%) was significantly lower in ACE-inhibitor naive patients with high CITP levels compared to ACE-inhibitor naive patients with low CITP levels (83.3%, P=0.003), to ACE-inhibitor users with low CITP levels (80%, P=0.006) and to ACE-inhibitor users with high CITP levels (70.4%, P=0.015). ACE-inhibitor related improvement in mortality was most predominant in chronic heart failure patients with high CITP levels. CITP levels possibly reflecting an activated status of the renin-angiotensin-aldosterone system, may be of clinical relevance since they identify a subgroup of patients that is more susceptible to treatment with an ACE-inhibitor.
Sofia V Chatzikyriakou; Dimitrios N Tziakas; Georgios K Chalikias; Dimitrios Stakos; Adina Thomaidi; Konstantina Mitrousi; Harisios Boudoulas
Related Documents :
3856239 - Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyop...
11420579 - Rationale and design of the canadian continuous positive airway pressure trial for cong...
18542839 - Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design ...
16198899 - Systolic and diastolic functions in elderly patients with and without heart failure.
21352529 - Computed tomographic assessment of lung weights in trauma patients with early posttraum...
11716889 - Beta-blockers, angiotensin ii, and ace inhibitors in patients with heart failure.
7489659 - Investigation of eeg non-linearity in dementia and parkinson's disease.
10230279 - Polyclonal, nonspecific 111in-igg scintigraphy in the evaluation of complicated osteomy...
16104949 - Vacuolating cytotoxin a is associated with increased thrombin generation in gastric muc...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2009-12-01
Journal Detail:
Title:  European journal of pharmacology     Volume:  628     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-27     Completed Date:  2010-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  164-70     Citation Subset:  IM    
University Cardiology Department, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Biological Markers / blood
Chronic Disease / drug therapy
Collagen Type I / metabolism*
Heart Failure / blood,  drug therapy*,  metabolism*
Survival Analysis
Treatment Outcome
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Biological Markers; 0/Collagen Type I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The alpha(2)-adrenoceptor agonist dexmedetomidine suppresses memory formation only at doses attenuat...
Next Document:  The hepatitis B viral X protein activates NF-kappaB signaling pathway through the up-regulation of T...